354 related articles for article (PubMed ID: 33225764)
21. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for brain cancer: recent progress and future promise.
Jackson CM; Lim M; Drake CG
Clin Cancer Res; 2014 Jul; 20(14):3651-9. PubMed ID: 24771646
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for glioma: Current management and future application.
Xu S; Tang L; Li X; Fan F; Liu Z
Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
[TBL] [Abstract][Full Text] [Related]
24. Histone H3K9 methyltransferase SETDB1 overexpression correlates with pediatric high-grade gliomas progression and prognosis.
Klonou A; Korkolopoulou P; Giannopoulou AI; Kanakoglou DS; Pampalou A; Gargalionis AN; Sarantis P; Mitsios A; Sgouros S; Papavassiliou AG; Piperi C
J Mol Med (Berl); 2023 Apr; 101(4):387-401. PubMed ID: 36811655
[TBL] [Abstract][Full Text] [Related]
25. Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.
Rallis KS; George AM; Wozniak AM; Bigogno CM; Chow B; Hanrahan JG; Sideris M
Cancer Genomics Proteomics; 2022; 19(4):390-414. PubMed ID: 35732328
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
Groves A; Cooney TM
Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
[TBL] [Abstract][Full Text] [Related]
27. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
29. Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.
Carpenter CD; Alnahhas I; Gonzalez J; Giglio P; Puduvalli VK
Expert Rev Neurother; 2019 Jul; 19(7):663-677. PubMed ID: 31106606
[No Abstract] [Full Text] [Related]
30. Emerging immune-based technologies for high-grade gliomas.
Giotta Lucifero A; Luzzi S
Expert Rev Anticancer Ther; 2022 Sep; 22(9):957-980. PubMed ID: 35924820
[TBL] [Abstract][Full Text] [Related]
31. Pre-clinical models for evaluating glioma targeted immunotherapies.
Frederico SC; Zhang X; Hu B; Kohanbash G
Front Immunol; 2022; 13():1092399. PubMed ID: 36700223
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials.
van Gool S
Immunotherapy; 2013 Oct; 5(10):1043-6. PubMed ID: 24138559
[TBL] [Abstract][Full Text] [Related]
33. Tumour immune landscape of paediatric high-grade gliomas.
Ross JL; Velazquez Vega J; Plant A; MacDonald TJ; Becher OJ; Hambardzumyan D
Brain; 2021 Oct; 144(9):2594-2609. PubMed ID: 33856022
[TBL] [Abstract][Full Text] [Related]
34. Concepts of immunotherapy for glioma.
Patel MA; Pardoll DM
J Neurooncol; 2015 Jul; 123(3):323-30. PubMed ID: 26070552
[TBL] [Abstract][Full Text] [Related]
35. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
36. STINGing the immune system: lessons learned through a model of G34-mutant pediatric high-grade glioma.
Hall CP; Cronk JC; Rubens JA
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377657
[TBL] [Abstract][Full Text] [Related]
37. Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors.
Sahebjam S; Stallworth DG; Mokhtari S; Tran ND; Arrington JA
Cancer Control; 2017 Apr; 24(2):180-186. PubMed ID: 28441372
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy for diffuse brainstem glioma in children and young adults.
Hu X; Fang Y; Hui X; Jv Y; You C
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD010439. PubMed ID: 27378212
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol.
Shah AH; Bregy A; Heros DO; Komotar RJ; Goldberg J
Neurosurgery; 2013 Nov; 73(5):863-7. PubMed ID: 23867302
[TBL] [Abstract][Full Text] [Related]
40. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
Perwein T; Giese B; Nussbaumer G; von Bueren AO; van Buiren M; Benesch M; Kramm CM
J Neurooncol; 2023 Feb; 161(3):525-538. PubMed ID: 36720762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
